• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA calls advisory panel for leadless pacemakers

FDA calls advisory panel for leadless pacemakers

December 14, 2015 By Brad Perriello

FDA logoThe FDA plans to ask an expert panel to come up with some guidelines for 1 of the next frontiers in cardiac rhythm management, the leadless pacemaker.

Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ) have each developed tiny pacers designed for transcatheter placement within the heart, eliminating the need for the wire leads used with conventional pacemakers; Boston Scientific (NYSE:BSX), which put its S-ICD subcutaneous-lead pacemaker on the U.S. market in September 2012, is also working on a truly leadless pacing implant.

The FDA said its Circulatory System Devices panel is slated to meet Feb. 18, 2016, for a hearing on how clinical trials, post-approval studies and physician training requirements should be structured for the devices.

The federal safety watchdog said it wants the committee to recommend acceptable adverse event rates in acute and chronic care settings, and to lay out the indications for use, “given availability of other technologies with different adverse event profiles.”

The panel is also tasked with recommending training requirements for surgeons implanting the devices, plus “acceptability of observed learning curves for the new device type,” the FDA said. The circulatory devices panel will also be asked for recommendations on post-approval study requirements, the agency said.

In November, Medtronic said its Micra leadless pacemaker met the primary safety and effectiveness endpoints in a 725-patient trial by “wide margins.” The Micra device won CE Mark approval in the European Union last April.

St. Jude likewise reported meeting 6-month safety and efficacy endpoints last August for its leadless pacemaker entry, the Nanostim device, in the 526-patient Leadless II trial.

Filed Under: Cardiovascular, Catheters, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Boston Scientific, Cardiac Rhythm Management, Medtronic, stjudemedical

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy